doi:10.15212/AMM-2022-0005 8
Research-Only Use Requirements These dosing guidelines are intended strictly for preclinical research purposes
Zhang J, Wu J, Du Y, Meng Y, Xiao S, Zhu H, Zhu Y (2025) 302MO phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic breast cancer (BC)
56 Our findings build on two previously reported PDAC-specific characteristics, namely, 1st RAS signaling driving glutamine metabolism for ROS homeostasis 22,50,51 and 2nd mitochondrial dependency upon genetic loss of the KRAS oncogene, 41 and connect them with a more generally described cancer cell state associated with therapy resistance, characterized by a dependence on lipid peroxidation defense pathways
We can help you sort out any B12 deficiency quite quickly once weve diagnosed it
Introduction 1